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Abstracts / Biol Blood Marrow Transplant 19 (2013) S257eS278 S265correlation with ICU admission, in-hospital death or death
within one year of transplant. Most stress test parameters
correlate poorly with outcomes of HSCT. Routine stress
testing is unlikely to be of signiﬁcant prognostic value. Stress
echocardiogram is of somewhat more value than stress
MUGA given that rest LVEF and exercise time correlate with
in-hospital death, but a standardized evaluation of exercise
capacity in the clinic and rest echo may be adequate sub-
stitutes.307
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Introduction: Busulfan (bu) is one of the most used
chemotherapy in conditioning regimens for patients
submitted to hematopoietic cell transplantation (HCT). As Bu
pharmacokinetic (PK) is widely variable, dose adjustment
according to patient PK has been shown to minimize toxic-
ities improving clinical outcome. Usually, PK is calculated
from blood samples collected after the ﬁrst Bu dose, guiding
adjustment of following doses. Although this method has
shown to be reliable, it can be difﬁcult to perform PK in an
optimal time frame. Therefore, using a test dose before HCT
can optimize this method, potentially given more accurate
dose adjustment. Bu test dose has been used with Bu iv
formulation, but little is knownwith oral Bu. In countries like
Brazil where oral Bu is still been used because of cost issues
an optimal drug administration should be developed.
Objectives: To validate the use of oral Bu test dose by
comparing PK from dose test and ﬁrst conditioning regimen
dose.
Methods: 19 patientes were enrolled. Median age was 28
year (range, 4-56). 4 (21%) patients received autologous HCT
while 19 (79%) allogeneic grafts from MRD or MUD donors.
As conditioning regimens, 1 patient recieved Bu(16)/
Flu(160), 9 Bu(16)/Cy(120), 3 Bu(16)Mel(140), 2 Bu(12)/
Cy(120)/Mel(140) and 4 Bu(12)/Cy(120)/Etoposide(1200).
After oral test dose (1mg/kg) 72 hours before conditioning
regimen, blood samples were collected at 8 time points.
Samples were also collected after the ﬁrst Bu dose (1mg/kg)
during conditioning regimen. Bu concentrations were
measured by HPLC. PK parameters were estimated by using
nonlinear mixed effects model computer program. No Bu
dose adjustment was performed based on test dose.Results: PK parameters were comparable between test dose
and ﬁrst conditioning dose: median Bu Clearance (microMol/
min) was 10115,9 (range: 333,43-18270,4) and 11866,1
(range: 4520,3-15589,2) respectively (P ¼ 0,738); median
concentration steady state (mcg/L) was 0,80 (range: 0,55-
1,59) and 0,76 (range: 0,59-1,23) respectively (P ¼ 0,672);
half life (hours) was 2,85 (range: 1,65-5,61) and 2,65 (range:
1,71-6,09) respectively (P ¼ 0,172). Area under the curve
(AUC) (mcgMol.min) was also comparable showing amedian
of 1174 (range: 799-2328) and 1110 (range: 857-1795)
respectively (P ¼ 0,679). Toxicities was comparable to liter-
ature data: 14 (88%) and 5 (12%) patients developed grades 1
to 3 and grade 4 mucositis respectively; 2 (10%) patients
developed sinuisodal obstruction syndrome (SOS) both
received Bu/Cy/Etoposide protocol. All patients achieved full
donor chimerism. Incidence of grade II-IV acute and exten-
sive chronic GVHD was 55% and 31% respectively. With
a median follow-up of 82 days (range: 18-321) 17 patients
were alive.
Conclusions: A population PK model for oral Bu could be
developed, showing efﬁcacy and safety of oral Bu test dose.308
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Background: Intravenous catheters are widely used in
hematopoietic stem cell transplant (HSCT) patients.
Complications associated with these catheters are frequently
encountered and contribute to morbidity, mortality, and
increased cost of treatment. Studies exploring such compli-
cations in this unique patient population are lacking. We
retrospectively studied infectious and thrombotic catheter-
related complications in acute myeloid leukemia (AML)
patients after undergoing HSCT at the largest tertiary referral
center in Oklahoma.
Methods: AML patients above the age of 18 who had HSCT at
The University of Oklahoma Health Sciences Center between
January, 2000 and June, 2012 were identiﬁed and medical
records were reviewed. Patients were stratiﬁed according to
age, ﬁrst HSCT type and type of catheter(s) present at or after
the ﬁrst HSCT (Hickman, peripherally inserted central cath-
eter (PICC) or infusion port (IP)). First blood stream infection
(BSI) and deep venous thrombosis (DVT) events after the ﬁrst
HSCT were reported (subsequent events were not included).
Statistical analysis was performed using SAS 9.2 software
(SAS Institute Inc.). Fisher's exact test was used to compare
patients in the different groups.
Results: 62 patients were included. Median age at diagnosis
was 44 years. 42 (68%) were males and 20 (32%) were
females. 53 (87%) were White, 4 (7%) Native American and 3
(5%) African American. 26 (43%) had sibling (SIB), 22 (36%)
unrelated donor (URD) and 13 (21%) double cord blood (DCB)
transplant. 56 (93%) had Hickman, 30 (50%) PICC and 7 (12%)
IP. 28 patients had one catheter type only (24 Hickman and 4
PICC). BSI occurred in 37% of all cases. BSI rates according to
the presence or absence of a particular catheter type were
38% vs. 33% for Hickman, 37% vs. 38% for PICC and 43% vs. 36%
for IP. In patients with only one catheter type, BSI rates were
38% for Hickman vs. 50% for PICC (P¼ .9). BSI occurred in 40%
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>50 years (P ¼ .56). Patients with DCB transplant had 63%
infections vs. 31% in the other transplant types (P ¼ .059).
Gram-positive cocci were isolated in 57% and Gram-negative
rods in 26% of all infections. DVT occurred in 26% of all cases.
DVT rates according to the presence or absence of a particular
catheter type were 27% vs. 25% for Hickman, 37% vs. 17% for
PICC (P ¼ .1) and 14% vs. 29% for IP (P ¼ .6). In patients with
only one catheter type, DVT rates were 17% for Hickman vs.
25% for PICC (P¼ .4). DVToccurred in 18% of patients 50 years
of age or younger and in 47% of those >50 years (P ¼ .026).
Conclusion: Among AML patients who underwent HSCT at
our institution, we did not observe any signiﬁcant differences
in catheter-related complications according to catheter type.
DVT rate was signiﬁcantly higher in patients older than 50
years. There was a trend of higher infection rate with double
cord blood transplant compared to other transplant types.309
Suicidal Protocol in Blood and Marrow Outpatient
Transplant Setting
Denise Kramer. Bone Marrow Transplant, Texas Oncology,
Dallas, TX
This information is intended to give background and inter-
vention options for healthcare professionals in the transplant
outpatient setting dealing with patients that are at risk for
suicide.
In 2007, there were 34,598 deaths by suicide in the United
States. Suicide is the fourth leading cause of death in adults,
ages 18 to 65 years. According to the Annals of Oncology
persons diagnosed with cancer have double the risk of
committing suicide compared to the general population.
It is important to identify those patients who are at greatest
risk of suicide. Symptoms of suicidal ideation include feelings
of hopelessness, anhedonia, insomnia, depression, severe
anxiety, impaired concentration, psychomotor agitation,
panic attack, and severe remorse. The Health Care Provider
needs to establish an atmosphere of trust to encourage the
patient to express their current symptoms. There are tools
available for health care providers in outpatient clinics that
can provide the ability to calculate the patient's risk. Some of
those tools include but are not limited to the Beck Scale, BSI
18, and SAFE T.
This program has experienced loss due to suicide in the past
several years. The program subsequently developed a suicide
protocol to help identify those patients at greatest risk for
suicide. The entire staff was trained on suicidal ideations and
at risk behaviors. When the staff identiﬁes a potential suicide
risk the team is called and further evaluation is completed.
The suicide protocol team consists of a nurse and social
worker. The process is explained to the patient and caregiver.
The nursemanager and the patient's physician are notiﬁed of
the situation. A family member or another staff member stay
with the patient at all times to maintain a safe environment.
We have identiﬁed a crisis team with a nearby psychiatric
facility that will provide further evaluation and recommend
a plan, if the patient is determined to be at risk for suicide. If
the patient appears safe to return home the patient and
family are instructed how tomake the home safe. The patient
will receive a follow up phone call and continued
monitoring.
Since the initiation of this protocol the facility has not had
a suicide attempt or completion.310
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Background: Radiation dermatitis is a frequent complication
following TBI based preparative regimens. There is no
consistent approach to the diagnosis and management of
radiation dermatitis. Many of the topical therapies have side
effects such as skin discoloration and discomfort in the case
of silver sulfadiazine. Newer silver containing agents such as
Silvasorb gel, Melgisorb Ag and Mepilex Ag may facilitate
healing and increase patient comfort.
Objective: To develop a consistent approach to diagnosis and
management of radiation dermatitis and to assess the clinical
outcomes in a pilot study.
Patients: From 2010 to 2012 thirteen patients who under-
went allogeneic BMT following a preparative regimen con-
sisting of 1200 cGy fractionated TBI and Cytoxan (60 mg/kg/
day x 2 days) were evaluated. All patients received daily
topical treatment with a moisturizing barrier cream (Aqua-
phor). Patients were evaluated daily for dermatitis. Radiation
dermatitis was graded according to CTCAE (version 3). Five
patients developed radiation dermatitis between days 0 to 2
post transplant.
Treatment and Results: All of the patients were treated
according to a previously developed algorithm. Two patients
with Grade 2 dermatitis were treated with Silvasorb gel
applied twice daily and reinforced with Xeroform gauze. The
skin lesions did not progress and was restored by day 5.
Three patients who progressed to Grade 3 dermatitis were
initially treated with Silvasorb gel, and the treatment was
changed to Melgisorb (ag) or Mepilex (ag). None of the
patients progressed to Grade 4. The skin lesions in all 3
patients with Grade 3 dermatitis was restored by Day 10 post
transplant and the therapy was discontinued.
Conclusions:
 CTCAE version 3 for assessing dermatitis represents
a useful and consistent tool for deﬁning radiation
dermatitis and allows for early intervention.
 The newer silver containing agents are well tolerated
and in this small series, effective in promoting healing.
 Based on our results an algorithm for early diagnosis
and treatment of grade 2-3 radiation dermatitis was
established.311
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